CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM's third capital market transaction five times oversubscribed

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year. Offering additional 150 million euros Term Loan B (TLB), final demand was close to 800 million euros. Thus, the company has become fully established on the capital market.

"Underpinned by the ratings of all three leading rating agencies – most recently Fitch Ratings assigned a B+ with stable outlook – we once again impressively won the trust of more than 50 investors and have now an outstanding TLB volume of nearly one billion euros", summarized CFO Jens Rothstein.

Besides benefitting from the supporting market environment, the background for the third capital market appearance was essentially the increase of the credit line, the optimization of interest terms and documentation of the TLB. Thus, CHEPLAPHARM has achieved greater flexibility in financing its ambitious corporate goals.

"The fact that we truly deserve the trust of our investors, our business partners and our employees is also confirmed by having just received the Axia Best Managed Company Award 2019 in May", CEO Sebastian F. Braun sums up the excellent outcome of the most recent transaction.

The Axia Best Managed Companies (BMC) program is a competition conducted by Deloitte, WirtschaftsWoche and BDI in Germany for successful medium-sized companies with the vision of building a national and global ecosystem of excellently managed mid-sized companies.

Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com


Investor Relations topics

Back to top expand_less